Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Myeloid Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Myeloid Neoplasm

Cancer Family

Myeloid Neoplasm

CI-CAN-00000279Explore in graph →

HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items

NCIt: C9290
OncoTree: MNM
DOID: 0070004

Overview
Statistics
Survival
Genomics22
Variants & evidence653
Drugs61
Trials4789
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (234)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 234 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
· Clin Cancer Res · 2013 · PMID 23969938 · validated civic_curation pubmed
Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.
· Br J Haematol · 2014 · PMID 24456122 · validated civic_curation pubmed
Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.
· Blood Cancer J · 2015 · PMID 25658984 · validated civic_curation pubmed
A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies.
· Blood · 2001 · PMID 11675361 · validated civic_curation pubmed
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
· Leukemia · 2012 · PMID 21818111 · validated civic_curation pubmed
Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.
· J Med Genet · 2010 · PMID 20543203 · validated civic_curation pubmed
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Showing 176–200 of 234 publications

← Previous
1
…
7
8
9
10
Next →

· Eur J Haematol · 2019 · PMID 30725494 · validated civic_curation pubmed

Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.

· Blood Adv · 2019 · PMID 31648321 · validated civic_curation pubmed

FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype.

· Pediatr Blood Cancer · 2017 · PMID 28097792 · validated civic_curation pubmed

Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG.

· Ann Hematol · 2018 · PMID 29427188 · validated civic_curation pubmed

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.

· Leukemia · 2014 · PMID 25212276 · validated civic_curation pubmed

Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions.

· Eur J Hum Genet · 2008 · PMID 18478040 · validated civic_curation pubmed

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

· Cancer Res · 2005 · PMID 15930265 · validated civic_curation pubmed

Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.

· Leukemia · 2004 · PMID 14737077 · validated civic_curation pubmed

An 8-year-old girl with secondary histiocytic sarcoma with BRAFV600 mutation following T-cell acute lymphoblastic leukemia demonstrating stable disease for 3 years on dabrafenib and trametinib - a case report and literature review.

· BMC Pediatr · 2025 · PMID 40057687 · validated civic_curation pubmed

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.

· Mol Cancer Ther · 2011 · PMID 21482694 · validated civic_curation pubmed

The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.

· Biochem Biophys Res Commun · 2004 · PMID 15194504 · validated civic_curation pubmed

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

· Leukemia · 2002 · PMID 12357354 · validated civic_curation pubmed

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

· Cancer Res · 2016 · PMID 27671675 · validated civic_curation pubmed

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

· J Clin Oncol · 2009 · PMID 19075254 · validated civic_curation pubmed

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.

· Mol Cancer · 2013 · PMID 23497317 · validated civic_curation pubmed

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

· Cancer Discov · 2017 · PMID 28193778 · validated civic_curation pubmed

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

· Blood · 2013 · PMID 24081659 · validated civic_curation pubmed

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.

· Invest New Drugs · 2017 · PMID 28516360 · validated civic_curation pubmed

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.

· Leukemia · 2013 · PMID 22858906 · validated civic_curation pubmed